Status:

ACTIVE_NOT_RECRUITING

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

Lead Sponsor:

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Conditions:

Sleep Restriction

Eligibility:

All Genders

60-80 years

Phase:

EARLY_PHASE1

Brief Summary

The purpose of this study is to 1) determine how hypothalamic-pituitary-adrenal axis (HPA axis) activation occurs with sleep restriction and 2) evaluate how hypothalamic-pituitary-gonadal axis (HPG ax...

Detailed Description

Sleep restriction and its consequences are major public health problems, especially in older adults. Among the more severe physiological sequelae of sleep restriction is the development of insulin res...

Eligibility Criteria

Inclusion

  • Men or postmenopausal women aged 60-80 years
  • Willingness to provide written informed consent
  • Stable weight over preceding 6 weeks
  • Body Mass index (BMI) 22-28 kg/m2
  • Physically and psychologically healthy
  • Good habitual sleep with regular bedtimes
  • Neither extreme morning- nor extreme evening-type using Horne-Ostberg Morningness-Eveningness criteria

Exclusion

  • Medications that interfere with the adrenal or gonadal axis will be excluded
  • Unable or unwilling to provide IRB (Internal Review Board)-approved informed consent
  • Clinical disorders and/or illnesses
  • Current medical or drug treatment, as assessed by questionnaire
  • History of brain injury or of learning disability
  • Vision or hearing impairment unless corrected back to normal
  • Anemia (Hct \<38%)
  • History of psychiatric illness
  • Clinically significant abnormalities in blood and urine, and free of traces of drugs
  • Other endocrine abnormalities including hypothyroidism or adrenal failure; primary gonadal disease as indicated by serum LH (luteinizing hormone) or FSH (follicle stimulating hormone) concentration \>10 or \>15 IU/L, respectively, hyperprolactinemia indicated by prolactin \>25ug/L
  • Type 2 Diabetes (HgbA1C)
  • Current smoker
  • Recent or concurrent drug or alcohol abuse
  • Blood donation in previous eight weeks
  • Travel across time zones within one month of entering the study
  • Sleep or circadian disorder
  • Shift work within three months of entering the study
  • Irregular bedtimes (not between 6 and 10 hours in duration)
  • Unoperated obstructive uropathy, recurrent prostatitis, indeterminate prostatic nodularity, Hx or Suspicion of cancer of the prostate gland or PSA (prostate-specific antigen) \>4ng/ml
  • Previous adverse reaction to sleep deprivation or any of the drugs to be administered
  • Concurrent participation in another research study
  • Mini- mental state examination (MMSE) \< 27

Key Trial Info

Start Date :

February 9 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 24 2026

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT04037605

Start Date

February 9 2020

End Date

June 24 2026

Last Update

September 11 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Los Angeles Biomedical Research Institute

Torrance, California, United States, 90509